Literature DB >> 9578842

Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity.

H Chong1, S Todryk, G Hutchinson, I R Hart, R G Vile.   

Abstract

Previously, we showed that expression of B7-1 in CMT93 murine colorectal tumour cells inhibited their growth in immunocompetent animals. However, this did not result in any significant increase in systemic protective immunity, relative to that elicited by the parental tumour. To potentiate the effects of B7-1 on systemic immunity. Interleukin-12 (IL-12) or granulocyte-macrophage colony-stimulating factor (GM-CSF) was co-expressed with this molecule. These combinations of immunostimulatory molecules were effective in eliciting systemic immunity. We also show that expression of B7-2 led to a local antitumour response as well as significantly raised systemic immunity. In another tumour model. K1735 minutes melanoma, which is moderately immunogenic, tumours secreting GM-CSF alone were as effective as the parental tumours in generating protective immunity. Previously, we described the deleterious effect of B7-1 expression on protective immunity. Co-expression of GM-CSF did not counteract this consequence of B7-1 expression. Expression of IL-12 was extremely effective in causing rejection of inoculated tumour cells, but evoked only minimal protective systemic immunity. These results suggest that combing costimulatory molecules and cytokines may be a useful therapeutic approach in some, but not all, tumours.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578842     DOI: 10.1038/sj.gt.3300584

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model.

Authors:  H R Galea; M Cogné
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 2.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

Authors:  Melissa G Lechner; Sarah M Russell; Rikki S Bass; Alan L Epstein
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

3.  Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines.

Authors:  S M Todryk; L J Birchall; R Erlich; N Halanek; J K Orleans-Lindsay; A G Dalgleish
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

4.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

5.  Bead-selected antitumor genetic cell vaccines.

Authors:  Mj Herrero; Botella R; Algás R; Fm Marco; Sf Aliño
Journal:  Clin Med Oncol       Date:  2008-03-25

6.  A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer.

Authors:  Na Wang; Jiwei Wang; Zhe Zhang; Hua Cao; Wenli Yan; Yongchao Chu; Louisa S Chard Dunmall; Yaohe Wang
Journal:  Mol Ther Oncolytics       Date:  2020-11-17       Impact factor: 7.200

7.  Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model.

Authors:  Antonio Miguel; María José Herrero; Luis Sendra; Rafael Botella; Rosa Algás; Maria Sánchez; Salvador F Aliño
Journal:  Toxins (Basel)       Date:  2012-10-31       Impact factor: 4.546

8.  Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12.

Authors:  K E Siapati; S Barker; C Kinnon; A Michalski; R Anderson; P Brickell; A J Thrasher; S L Hart
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.